ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
Author: Global Cancer Consortium
The U.S. Preventive Services Task Force recommended this week that women should begin getting routine mammograms at the age of 50 instead of the previously recommended age of 40.
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.
Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer.
Bioniche Life Sciences has received its first milestone payment of $6 million from Endo Pharmaceuticals for its experimental bladder cancer drug.
A clinical trial by Guided Therapeutics (GT), a biotechnology company specializing in women’s health, found that current screening methods for cervical disease missed the disease nearly a third of the time.
GenVec’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration.
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.